---
document_datetime: 2025-04-22 14:20:52
document_pages: 21
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kuvan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kuvan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.8178055
conversion_datetime: 2025-12-20 01:36:27.563072
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kuvan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0079              | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 08/11/2024                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0078            | Submission of the final report from study KOGNITO, listed as a category 3 study in the RMP. This is a Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4-to 5-Year- Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan) for 7 Years. The RMP version 16.1 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | 13/06/2024   | n/a   |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IA/0077            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/07/2023   | n/a   |                                   |
| IA/0076/G          | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                         | 05/09/2022   | n/a   |                                   |
| PSUSA/2683/ 202112 | Periodic Safety Update EU Single assessment - sapropterin                                                                                                                                                                                                                                                                                                                                                                                                                                             | 07/07/2022   | n/a   | PRAC Recommendation - maintenance |
| II/0073            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                         | 07/07/2022   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0075   | B.II.f.z - Stability of FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                          | 23/03/2022   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0072   | B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue                                                                                                                                                                                                                                                     | 15/12/2021   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0071   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                            | 15/04/2020   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0070/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 10/04/2020   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0068   | Update of Section 5.1 of the Summary Product Characteristics (SmPC) in order to reflect new paediatric information based on study PKU-015 evaluating the effect of Kuvan on neurocognitive function, maintenance of blood phenylalanine concentrations, safety, and population pharmacokinetics in young children with phenylketonuria.                                                                                                               | 16/01/2020   | 04/02/2021 | SmPC | Based on the review of the submitted data, new clinical SmPC information (section 5.1) related to the long term efficacy and safety of Kuvan was added. In young children with phenylketonuria (PKU), efficacy parameters were within the average range for the normative population. No additional adverse reactions were identified with long-term use of Kuvan for a mean duration of 6.5 years in children |

<div style=\"page-break-after: always\"></div>

|                    | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                       |            |     | less than 7 years of age at study entry.   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------|
| IB/0069            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                           | 28/10/2019 | n/a |                                            |
| PSUSA/2683/ 201812 | Periodic Safety Update EU Single assessment - sapropterin                                                                                                                                                                                                                                                                                                                                                                               | 14/06/2019 | n/a | PRAC Recommendation - maintenance          |
| IAIN/0067/G        | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                     | 05/04/2019 | n/a |                                            |
| IA/0066/G          | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) | 17/03/2019 | n/a |                                            |

<div style=\"page-break-after: always\"></div>

| IB/0064/G II/0061   | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) Update of section 5.2 of the Summary of Product Characteristics (SmPC) for Kuvan in order to update the information related to the interaction with P- glycoprotein (P-gp) and breast cancer resistant protein (BCRP). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 15/02/2019 24/01/2019   | n/a 20/05/2019   | SmPC   | Based on the submission of drug-drug interaction study performed in 24 healthy subjects to investigate the effects of Kuvan on the pharmacokinetics of a sensitive P-gp substrate (digoxin) when given concomitantly, section 5.2 was updated to include further information on the potential for Kuvan to inhibit p-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in the gut at the therapeutic doses. In healthy subjects, administration of a single dose of Kuvan at the maximum therapeutic dose of 20 mg/kg had no effect on the pharmacokinetics of a single dose of digoxin (P-gp substrate) administered concomitantly. Based on the in vitro and in vivo results, co-administration of   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0063/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/01/2019              | n/a              |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process       |            |            |             | manufacturing site for   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------|
| II/0060   | Update of the section 4.8 of the Summary of Product Characteristics (SmPC) to add oesophagitis as a new adverse drug reaction with a frequency unknown. The Package Leaflet (PL) is updated accordingly and editorial changes are made related to the information on sodium content in the SmPC and PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 11/10/2018 | 20/05/2019 | SmPC and PL | data                     |
| IA/0062/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                           | 30/08/2018 | n/a        |             | procedure                |

<div style=\"page-break-after: always\"></div>

| PSUSA/2683/ 201712   | Periodic Safety Update EU Single assessment - sapropterin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/06/2018   | n/a        |                        |              |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------|
| II/0059              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                   | 07/06/2018   | 20/05/2019 | SmPC                   |              |
| II/0052              | Based on a review of the post-marketing experience and in order to harmonise the safety information with the CCDS, update of section 4.8 of the Kuvan SmPC to add the following adverse events regarding gastrointestinal tract: dyspepsia, nausea and gastritis. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement the latest QRD template and bring up to date sections 17 and 18 of Annex IIIA. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 12/04/2018   | 12/06/2018 | SmPC, Labelling and PL | data         |
| IA/0056/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) Change in shape or dimensions of the                                                                                                                                                                                      | 06/03/2018   | n/a        |                        | B.II.e.4.a - |

<div style=\"page-break-after: always\"></div>

|           | closure (immediate packaging) - Non- sterile medicinal products B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                     |            |            |                     | container or   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|----------------|
| IB/0054/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished | 05/01/2018 | n/a        |                     | product        |
| IB/0055   | B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                          | 21/12/2017 | n/a        |                     |                |
| X/0047    | Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/05/2017 | 13/07/2017 | SmPC, Labelling and |                |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0048/G          | This was an application for a group of variations. Update of section 4.9 of the SmPC to add information regarding shortening of QT interval at high doses following review of data of study QTC-001. Submission of the clinical study report EMR700773- 004 (pilot study assessing the effect of sapropterin on cognitive abilities, study prematurely terminated due to enrolment issues) In addition, the MAH took the opportunity of this procedure to clarify the wording of section 4.2 and section 3 of the PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 22/06/2017 | 12/06/2018 | SmPC and PL | Following the review of data of study QTC-001, a phase I study to assess the effect of Kuvan at supra-therapeutic dose on QTc intervals, it was agreed to update the SmPC section 9 to add information that shortening of the QT interval was observed and should be taken into consideration in managing patients who have a pre-existing shortened QT interval. |
| PSUSA/2683/ 201612 | Periodic Safety Update EU Single assessment - sapropterin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/06/2017 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                 |
| IB/0050            | B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/04/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| II/0046   | Update of section 4.5 to delete the statement that no interaction studies have been performed and section 5.2 to reflect the relevant results of in vitro pharmacokinetic drug interactions studies BMN162- 14-021, 022, 023, BMN162-15-036 and 101. In addition, the MAH took the opportunity of this procedure to improve the wording of section 4.2 and implement minor administrative changes in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 23/03/2017   | 13/07/2017   | SmPC   | Following the review of in vitro studies BMN162-14-021, 022, 023, BMN162-15-036 and 101, the CHMP agrees that sapropterin did not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5, nor induce CYP1A2, 2B6, or 3A4/5. This information is reflected in section 5.2 of the SmPC.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0051   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                   | 17/03/2017   | n/a          |        |                                                                                                                                                                                                                                                                                                      |
| IB/0045/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.4.b - Change to in-process tests or limits  | 05/10/2016   | n/a          |        |                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| applied during the manufacture of a new in-process test B.I.b.1.c - Change in the and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.d.1.c - Stability of period/storage period to an approved stability B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or   | batch   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|

<div style=\"page-break-after: always\"></div>

| PSUSA/2683/ 201512   | Periodic Safety Update EU Single assessment - sapropterin                                                                                                                                                                              | 09/06/2016   | n/a        |                        | PRAC Recommendation - maintenance                                                                |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------|
| IAIN/0044            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                     | 25/05/2016   | n/a        |                        |                                                                                                  |
| IAIN/0043            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                     | 18/03/2016   | n/a        |                        |                                                                                                  |
| IAIN/0041            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 27/01/2016   | 11/01/2017 | Annex II and PL        |                                                                                                  |
| T/0040               | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 25/11/2015   | 07/01/2016 | SmPC, Labelling and PL |                                                                                                  |
| IA/0039              | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                   | 07/08/2015   | n/a        |                        |                                                                                                  |
| IB/0038              | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                             | 30/07/2015   | n/a        |                        |                                                                                                  |
| II/0033              | Extension of indication for the 'treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of 4 years of age and over with                                                                                           | 21/05/2015   | 22/06/2015 | SmPC and PL            | Please refer to the scientific discussion Kuvan EMEA/H/C/000943/II/0033 for further information. |

<div style=\"page-break-after: always\"></div>

|                    | phenylketonuria (PKU) who have shown to be responsive to such treatment' to include the paediatric population of all ages. Consequently, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly. The requested variation proposed amendments to the SmPC and Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |      |                                                                                                                                                                                                                                                                                                                                    |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2683/ 201412 | Periodic Safety Update EU Single assessment - sapropterin                                                                                                                                                                                                                                                                                                                                                                                               | 11/06/2015 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                  |
| II/0032            | To change an impurity limit of the finished product. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                                                                                                                                                                | 22/01/2015 | n/a        |      |                                                                                                                                                                                                                                                                                                                                    |
| II/0034            | Update of section 4.6 of the SmPC following the evaluation of pregnancy data from MAH-sponsored trials, post-marketing safety database and literature. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                | 18/12/2014 | 22/06/2015 | SmPC | Following the evaluation of pregnancy data from sponsored trials, post-marketing safety database and literature, section 4.6 of the SmPC has been updated to reflect the data available. These up-to-date data support confirmed that the notion that dietary control of blood phenylalanine levels during pregnancy is necessary. |
| IA/0036/G          | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                       | 10/12/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |     |                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/0500   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                       | 17/11/2014 | n/a |                                   |
| IG/0461   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                       | 22/07/2014 | n/a |                                   |
| PSUV/0029 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                | 12/06/2014 | n/a | PRAC Recommendation - maintenance |
| IB/0030/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                              | 16/05/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| R/0026    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/09/2013   | 13/11/2013   | SmPC, Annex II, Labelling and PL   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|
| IA/0028   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                      | 12/11/2013   | n/a          |                                    |
| IB/0027   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 13/08/2013   | n/a          |                                    |
| IA/0025   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/02/2013   | n/a          |                                    |
| IB/0022/G | This was an application for a group of variations. B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter as a result of a safety or quality issue B.I.b.1.c - Change in the specification parameters | 03/12/2012   | n/a          |                                    |

<div style=\"page-break-after: always\"></div>

|           | - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |     | material/intermediate/reagent   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------|
| IA/0024/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 29/10/2012 | n/a |                                 |
| IG/0224   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 11/10/2012 | n/a |                                 |
| IB/0018/G | This was an application for a group of variations. B.I.b.1.h - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/06/2012 | n/a |                                 |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter as a result of a safety or quality issue B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   |            |            |             |                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 15/06/2012 | n/a        |             |                                                                                                                                                                     |
| II/0015   | Update of section 4.8 of the SmPC following assessment of the 5th PSUR, to reflect cases of hypersensitivity that have been reported. The                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 19/04/2012 | 25/05/2012 | SmPC and PL | In August 2011 the MAH submitted the 5th PSUR including the relevant safety information for Kuvan. The CHMP concluded in the assessment report that the SmPC should |

<div style=\"page-break-after: always\"></div>

|           | Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH   |            |     | be updated regarding hypersensitivity/allergic reactions and anaphylactic type reactions. This variation addresses this request. The review of the cumulative post-marketing data presented in the 5th PSUR shows that a causal role of Kuvan in the development of 'allergic reactions', 'asthma' or 'rash' could not be established in most of the cases. However, isolated reports suggest that the administration of Kuvan may be associated with hypersensitivity. Twenty reports of hypersensitivity reactions were identified by the MAH. In two of these cases the reported hypersensitivity reactions were observed within a rather short temporal link in the absence of history of allergies, which may suggest some relationship with the treatment. In three other cases reporting skin rash, a positive rechallenge was reported, which appear to support, with a reasonable possibility, a causal relationship. As the causal association between Kuvan and hypersensitivity reactions cannot be excluded for these cases, the product information regarding allergic/hypersensitivity reactions has been updated. This new identified risk does not affect the benefit/risk ratio   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0016/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters                                                                                          | 11/04/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0014   | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/12/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0012   | Following the review of the PSUR 3, MAH has applied to update SmPC to reflect changes in the reporting of convulsion cases in the sections 4.4 and 4.5 of the SmPC. In addition, numbers in the section 5.1 of the SmPC have been rounded for better readability. The MAH also took the opportunity to update Annex IIB \"Other conditions\" with the latest wording as per October 2010 CHMP announcement regarding the Pharmacovigilance system and to update local representatives in the Package Leaflet. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 23/06/2011 | 26/07/2011 | SmPC, Annex II and PL | Following the review of the PSUR 3 the CHMP recommended reviewing the product information in order to accurately reflect the post marketing reports of convulsion. The MAH therefore applied to amend Product Information. The risk of convulsion was evaluated using various sources including 10-year post-marketing surveillance program, Merck Serono Safety Database and literature review. Subsequently the sections 4.4 \"Special warnings and Precautions for use\" and 4.5 \"Interactions with other medicinal products and other forms of interaction\" of the current SmPC have been updated to reflect changes to the Core Data Sheet to reflect data in relation to convulsions and exacerbation of convulsions. |
| IG/0076/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 01/07/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                      |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0011  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                     | 21/12/2010 | 21/01/2011 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                      |
| IB/0010 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                               | 10/06/2010 | n/a        | SmPC                   |                                                                                                                                                                                                                                                                                                                                                      |
| II/0007 | Update of the Detailed Description of the Pharmacovigilance system (DDPS). Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                           | 22/04/2010 | 12/05/2010 | Annex II               | With this variation the MAH submitted a new version of the DDPS (core version 9.0) in accordance with the current Pharmacovigilance guideline. After assessing the documentation the CHMP concluded that the submitted DDPS contained all required elements. Consequently, Annex II has been updated with the new version number of the agreed DDPS. |
| IA/0009 | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                              | 25/03/2010 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                      |
| II/0006 | Introduction of an alternative manufacturing process for the active substance. Quality changes                                                                                                                                                                                                                          | 18/03/2010 | 24/03/2010 |                        |                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0008/G   | a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products   | 23/03/2010   | n/a        |                 | This was an application for   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------|
| II/0003     | Change in an in-process control of the finished product. Quality changes                                                                                                                                                                                                                                                                                            | 23/07/2009   | 12/08/2009 |                 |                               |
| IB/0005     | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                                                                                                            | 07/08/2009   | n/a        |                 |                               |
| N/0004      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                    | 30/06/2009   | n/a        | PL              |                               |
| IA/0002     | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                                                                                                                                                                                                    | 19/12/2008   | n/a        | Annex II and PL |                               |
| IA/0001     | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                            | 19/12/2008   | n/a        |                 |                               |